United States · FDA National Drug Code directory
Naropin
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 63323-287_cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9
- Product NDC
- 63323-287
- Form
- INJECTION, SOLUTION
- Composition / generic term
- ROPIVACAINE HYDROCHLORIDE
- Labeler
- Fresenius Kabi USA, LLC
- Marketing category
- NDA
- Marketing start / end (source format)
- 19960924
- Source listing expiry
- 20261231
Source-listed ingredients
- ROPIVACAINE HYDROCHLORIDE — 7.5 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 5 AMPULE in 1 BOX (63323-287-20) / 20 mL in 1 AMPULE (63323-287-01) · 63323-287-20
- 25 VIAL, SINGLE-DOSE in 1 CARTON (63323-287-21) / 20 mL in 1 VIAL, SINGLE-DOSE (63323-287-03) · 63323-287-21
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →